Merck decision to bail from TLR9 agonist programme upsets Idera investors
This article was originally published in Scrip
Idera Pharmaceuticals did its best to try to console investors after its partner Merck KGaA decided to terminate further development of IMO-2055, a toll-like receptor 9 (TLR9) agonist, due to an increase in neutropenia and electrolyte imbalances reported in its Phase Ib trial in patients with first-line squamous cell carcinoma of the head and neck (SCCHN), pointing out that the partnership remained intact and the big pharma still planned to at least complete an ongoing Phase II study and would continue its pursuit of follow-on TLR9 agonists created under the collaboration.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.